Answers are grounded in this paper and cite their sources.
This Viewpoint provides suggestions to address challenges after elimination of the Clozapine Risk Evaluation and Mitigation Strategies (REMS) system by the US Food and Drug Administration (FDA).
No takes yet. Share an insight, caveat, or question.
Kelly et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: